|  |
| --- |
| **Paediatric Inflammatory Multisystem Syndrome**  The Australian Health Protection Principal Committee (AHPPC) has responded to recent reports linking Kawasaki Disease and COVID-19 by releasing this statement:   AHPPC has considered advice from the Acute Inflammatory Vasculitis Working Group and the Paediatric Active Enhanced Disease Surveillance, regarding a condition provisionally named Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-COV-2 (PIMS TS).  PIMS-TS is a newly described condition in children with features that overlap with Kawasaki Disease (KD) and Toxic Shock Syndrome (TSS); it appears to be associated with COVID-19 in certain circumstances.  To date, PIMS-TS has been reported in children from countries such as the USA, UK and Europe who are experiencing widespread community-based transmission of SARS-CoV-2 and thus, much higher rates of paediatric disease. COVID-19 in children is less common and typically a mild disease. PIMS-TS appears to be rare but worthy of better understanding.  The overall risk for any severe COVID-19 outcomes in children in the Australian context remains extremely low and no cases of PIMS-TS have been identified in Australia at this time. However, AHPPC supports:  •    enhanced surveillance capabilities for this and related conditions in Australia during the COVID-19 pandemic. •    communication to paediatricians and general practitioners to make them aware of this potential complication of COVID-19. •    cooperation with paediatricians, surveillance and research networks internationally regarding further developments. |